Shimpei Morimoto

778 total citations
45 papers, 315 citations indexed

About

Shimpei Morimoto is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Physiology. According to data from OpenAlex, Shimpei Morimoto has authored 45 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Epidemiology and 7 papers in Physiology. Recurrent topics in Shimpei Morimoto's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Shimpei Morimoto is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Shimpei Morimoto collaborates with scholars based in Japan, United States and United Kingdom. Shimpei Morimoto's co-authors include Atsushi Kawakami, Naoki Iwamoto, Hideki Nakamura, Shoichi Fukui, Kaori Furukawa, Kunihiro Ichinose, Tomohiro Koga, Hiroshi Mukae, Shin‐ya Kawashiri and Mami Tamai and has published in prestigious journals such as Scientific Reports, PLoS Medicine and Frontiers in Immunology.

In The Last Decade

Shimpei Morimoto

42 papers receiving 309 citations

Peers

Countries citing papers authored by Shimpei Morimoto

Since Specialization

Citations

This map shows the geographic impact of Shimpei Morimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shimpei Morimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shimpei Morimoto more than expected).

Fields of papers citing papers by Shimpei Morimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shimpei Morimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shimpei Morimoto. The network helps show where Shimpei Morimoto may publish in the future.

Co-authorship network of co-authors of Shimpei Morimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Shimpei Morimoto. A scholar is included among the top collaborators of Shimpei Morimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shimpei Morimoto. Shimpei Morimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Nintedanib in Japanese Patients With Early-Stage Idiopathic Pulmonary Fibrosis: A One-Year Interim Analysis from a Multicenter Observational Study in Kyushu and Okinawa, Japan 2025 ·Clinical Therapeutics ·Noriho Sakamoto, Masaki Okamoto, Kazunori Tobino, Hidenori Ichiyasu, Kazuya Ichikado, Hiroshi Ishii, Naoki Hamada, Kazuhiro Yatera, Taiga Miyazaki, Hiroshi Ishimoto, Takashi Kido, (unknown), Shimpei Morimoto, Naoki Hosogaya, Hiroshi Mukae	0
2	A Phase-II Investigator-Initiated Randomized, Double-Blind, Parallel-Group Clinical Trial of 5-Aminolevulinic Acid Hydrochloride/Sodium Ferrous Citrate (5-ALA-HCl/SFC) for Patients With Adult-Onset Still’s Disease (AOSD) Refractory to Corticosteroids 2025 ·Cureus ·Remi Sumiyoshi, Tomohiro Koga, (unknown), Shimpei Morimoto, Naoki Hosogaya, Hiroshi Yamamoto, Mariko Kawakami, Yosuke Inaba, Yoko Hattori, (unknown), (unknown), Hideki Hanaoka, Shuzo Sato, Kiyoshi Migita, (unknown), Motomu Hashimoto, Atsushi Kawakami	0
3	A Phase Ib Investigator-Initiated Trial of Filgotinib in Patients With Idiopathic Multicentric Castleman Disease 2025 ·Cureus ·Shoichi Fukui, Remi Sumiyoshi, Tomohiro Koga, Naoki Hosogaya, (unknown), Shimpei Morimoto, Hiroshi Yano, (unknown), Shingo Yano, Yasufumi Masaki, Shinichiro Tsunoda, Shuzo Sato, Kiyoshi Migita, (unknown), Naoki Kato, Atsuhiko Kawamoto, Atsushi Kawakami	0
4	The prognostic factors for cryptococcal meningitis in non‐human immunodeficiency virus patients: An observational study using nationwide database 2023 ·Mycoses ·(unknown), Takahiro Takazono, (unknown), Shimpei Morimoto, Yuya Ito, (unknown), Nobuyuki Ashizawa, Tatsuro Hirayama, (unknown), Naoki Iwanaga, Masato Tashiro, Naoki Hosogaya, Takeshi Tanaka, Kiyohide Fushimi, Katsunori Yanagihara, Hiroshi Mukae, Koichi Izumikawa	7
5	Association between Lifestyle Factors and Weight Gain among University Students in Japan during COVID-19 Mild Lockdown: A Quantitative Study 2023 ·Healthcare ·(unknown), Norio Abiru, Shimpei Morimoto, Tomoya Nishino, Atsushi Kawakami, (unknown), Masakazu Kobayashi	1
6	Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study 2023 ·Lara D. Veeken ·(unknown), Naoki Iwamoto, Shoichi Fukui, Shimpei Morimoto, Toshiyuki Aramaki, (unknown), (unknown), Katsumi Eguchi, Yukitaka Ueki, Atsushi Kawakami	23
7	Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial 2023 ·Trials ·Toshimasa Shimizu, Shin‐ya Kawashiri, Shimpei Morimoto, (unknown), (unknown), (unknown), Yasuko Ito, (unknown), Shuntaro Sato, Hiroshi Yamamoto, Atsushi Kawakami	4
8	The fecal carriage rate of extended-spectrum β-lactamase–producing or carbapenem-resistant Enterobacterales among Japanese infants in the community at the 4-month health examination in a rural city 2023 ·Frontiers in Cellular and Infection Microbiology ·Soichiro Kawata, Shimpei Morimoto, Kosuke Kosai, (unknown), Yumiko Nakashima, Yoshitomo Morinaga, Katsunori Yanagihara, Lay‐Myint Yoshida, Hiroyuki Moriuchi	4
9	Predictive values of immune indicators on respiratory failure in the early phase of COVID-19 due to Delta and precedent variants 2023 ·Frontiers in Immunology ·Kentaro Nagaoka, Hitoshi Kawasuji, (unknown), Y Murai, Makito Kaneda, (unknown), Shimpei Morimoto, (unknown), Hideki Niimi, Yoshitomo Morinaga, Yoshihiro Yamamoto	3
10	Comparison of liposomal amphotericin B alone and in combination with flucytosine in the treatment of non‐HIV Cryptococcal meningitis: A nationwide observational study 2022 ·Mycoses ·Takahiro Takazono, (unknown), Shimpei Morimoto, Masato Tashiro, Nobuyuki Ashizawa, Tatsuro Hirayama, (unknown), Naoki Iwanaga, Naoki Hosogaya, Kazuko Yamamoto, Kiyohide Fushimi, Katsunori Yanagihara, Hiroshi Mukae, Koichi Izumikawa	3
11	Infectious Pneumonia and Lower Airway Microorganisms in Patients with Rheumatoid Arthritis 2021 ·Journal of Clinical Medicine ·(unknown), Kazuko Yamamoto, Masahiro Tahara, Tomohiro Koga, Shotaro Ide, Tatsuro Hirayama, Takahiro Takazono, Yoshifumi Imamura, Taiga Miyazaki, Noriho Sakamoto, Shimpei Morimoto, Koichi Izumikawa, Katsunori Yanagihara, Kazuto Ashizawa, Takatoshi Aoki, Atsushi Kawakami, Kazuhiro Yatera, Hiroshi Mukae	2
12	Evaluation of sweating responses in patients with collagen disease using the quantitative sudomotor axon reflex test (QSART): a study protocol for an investigator-initiated, prospective, observational clinical study 2021 ·BMJ Open ·(unknown), Tomohiro Koga, Shimpei Morimoto, (unknown), (unknown), Yuta Koike, Hiroyuki Murota	3
13	HLA-B54 is an independent risk factor for pneumonia in Japanese patients with interstitial lung disease: A multicenter retrospective cohort study 2021 ·Respiratory Medicine ·Noriho Sakamoto, Hiroshi Ishimoto, Masahiro Tahara, Takashi Kido, Atsuko Hara, Takuto Miyamura, (unknown), (unknown), Sumako Yoshioka, Shimpei Morimoto, Takahiro Takazono, Kazuko Yamamoto, Hiroyuki Yamaguchi, Yasushi Obase, Yuji Ishimatsu, Kazuhiro Yatera, Hiroshi Mukae	1
14	Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study 2021 ·PLoS Medicine ·Shoya Iwanami, Keisuke Ejima, Kwang Su Kim, Koji Noshita, Yasuhisa Fujita, Taiga Miyazaki, Shigeru Kohno, Yoshitsugu Miyazaki, Shimpei Morimoto, Shinji Nakaoka, Yoshiki Koizumi, Yusuke Asai, Kazuyuki Aihara, Koichi Watashi, Robin N. Thompson, Kenji Shibuya, Katsuhito Fujiu, Alan S. Perelson, Shingo Iwami, Takaji Wakita	30
15	Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study 2021 ·BMJ Open ·Noriho Sakamoto, Naoki Hamada, Masaki Okamoto, Kazunori Tobino, Hidenori Ichiyasu, Hiroshi Ishii, Kazuya Ichikado, Shimpei Morimoto, Naoki Hosogaya, Hiroshi Mukae	2
16	The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT) 2020 ·Trials ·(unknown), (unknown), Ichiro Horie, Shimpei Morimoto, Ayako Ito, Ko Chiba, (unknown), Shigeki Tashiro, (unknown), Shuntaro Sato, Hiroshi Yamamoto, Makoto Osaki, Atsushi Kawakami, Norio Abiru	6
17	Comparison of lung microbiota between antineutrophil cytoplasmic antibody-associated vasculitis and sarcoidosis 2020 ·Scientific Reports ·Shoichi Fukui, Shimpei Morimoto, Kunihiro Ichinose, Shota Nakashima, Hiroshi Ishimoto, Atsuko Hara, Tomoyuki Kakugawa, Noriho Sakamoto, (unknown), Toshiyuki Aramaki, Tomohiro Koga, Shin‐ya Kawashiri, Naoki Iwamoto, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Yukitaka Ueki, Shino Suzuki, Hiroshi Mukae, Atsushi Kawakami	7
18	Risk factors associated with the development of aspiration pneumonia in patients receiving radiotherapy for head and neck cancer: retrospective study 2020 ·Head & Neck ·Yumiko Kawashita, Shimpei Morimoto, Kensuke Tashiro, Sakiko Soutome, Masako Yoshimatsu, Noriko Nakao, (unknown), (unknown), Takashi Ukai, Masahiro Umeda	8
19	A score using left ventricular diastolic dysfunction to predict 90-day mortality in acute ischemic stroke: The DONE score 2019 ·Journal of the Neurological Sciences ·Yohei Tateishi, (unknown), (unknown), Shunsuke Yoshimura, Teiichiro Miyazaki, Hirokazu Shiraishi, Shimpei Morimoto, Akira Tsuneto, Koji Maemura, Yoichi Morofuji, Nobutaka Horie, Tsuyoshi Izumo, Akira Tsujino	5
20	Identification of stress responsive genes by studying specific relationships between mRNA and protein abundance 2018 ·Heliyon ·Shimpei Morimoto, Koji Yahara	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact